GO
Loading...

Gilead Sciences Inc

More

  • Final Glance: Biotechnology companies Friday, 17 Apr 2015 | 6:03 PM ET

    Amgen Inc. fell $3.29 or 2.0 percent, to $163.58. Biogen Idec fell $9.21 or 2.1 percent, to $419.44. Celgene Corp. fell $2.89 or 2.5 percent, to $113.47.

  • Midday Glance: Biotechnology companies Friday, 17 Apr 2015 | 1:17 PM ET

    Amgen Inc. fell $4.27 or 2.6 percent, to $162.60. Biogen Idec fell $8.80 or 2.1 percent, to $419.85. Celgene Corp. fell $2.47 or 2.1 percent, to $113.89.

  • Early Glance: Biotechnology companies Friday, 17 Apr 2015 | 10:57 AM ET

    Amgen Inc. fell $3.39 or 2.0 percent, to $163.48. Biogen Idec fell $7.44 or 1.7 percent, to $421.21. Celgene Corp. fell $2.02 or 1.7 percent, to $114.34.

  • Final Glance: Biotechnology companies Thursday, 16 Apr 2015 | 6:03 PM ET

    Amgen Inc. rose $1.40 or. 8 percent, to $166.87. Biogen Idec fell $2.31 or. 5 percent, to $428.65. Celgene Corp. fell $1.87 or 1.6 percent, to $116.36.

  • Midday Glance: Biotechnology companies Thursday, 16 Apr 2015 | 1:28 PM ET

    Amgen Inc. rose $1.15 or. 7 percent, to $166.62. Biogen Idec fell$. 01 or percent, to $430.95. Celgene Corp. fell $1.65 or 1.4 percent, to $116.58.

  • Final Glance: Biotechnology companies Wednesday, 15 Apr 2015 | 5:57 PM ET

    Amgen Inc. rose $2.90 or 1.8 percent, to $165.47. Biogen Idec rose $7.39 or 1.7 percent, to $430.96. Celgene Corp. rose $2.45 or 2.1 percent, to $118.23.

  • Midday Glance: Biotechnology companies Wednesday, 15 Apr 2015 | 2:34 PM ET

    Amgen Inc. rose $1.99 or 1.2 percent, to $164.56. Biogen Idec rose $6.10 or 1.4 percent, to $429.67. Celgene Corp. rose $1.68 or 1.5 percent, to $117.46.

  • Final Glance: Biotechnology companies Tuesday, 14 Apr 2015 | 5:58 PM ET

    Amgen Inc. rose$. 08 or percent, to $162.57. Biogen Idec rose$. 21 or percent, to $423.57. Celgene Corp. fell$. 66 or. 6 percent, to $115.78.

  • Midday Glance: Biotechnology companies Tuesday, 14 Apr 2015 | 1:34 PM ET

    Amgen Inc. fell$. 70 or. 4 percent, to $161.79. Biogen Idec fell $3.32 or. 8 percent, to $420.04. Celgene Corp. fell $1.10 or. 9 percent, to $115.34.

  • Early Glance: Biotechnology companies Tuesday, 14 Apr 2015 | 10:42 AM ET

    Amgen Inc. fell $1.12 or. 7 percent, to $161.37. Biogen Idec fell $3.22 or. 8 percent, to $420.14. Celgene Corp. fell$. 43 or. 4 percent, to $116.01.

  • A record 4.3 billion prescriptions were filled in 2014, many of them for inexpensive generic pills going to patients now insured through Medicaid in states that expanded eligibility for the government health program for the poor and disabled. The number of prescriptions covered by Medicaid rose by nearly 17 percent, and that increase accounted for 70...

  • Demand for newer cancer and multiple sclerosis treatments, price increases on branded medicines, particularly insulin products for diabetes, and the entry of few new generic versions of big-selling drugs also contributed to the double-digit spending rise in 2014, the report by IMS Health Holdings Inc found. "We certainly expect to see growth in the market...

  • Final Glance: Biotechnology companies Monday, 13 Apr 2015 | 6:00 PM ET

    Amgen Inc. fell$. 89 or. 5 percent, to $162.49. Biogen Idec fell $2.29 or. 5 percent, to $423.36. Celgene Corp. fell$. 63 or. 5 percent, to $116.44.

  • Midday Glance: Biotechnology companies Monday, 13 Apr 2015 | 1:19 PM ET

    Amgen Inc. fell$. 05 or percent, to $163.33. Biogen Idec rose $1.39 or. 3 percent, to $427.04. Celgene Corp. rose$. 52 or. 4 percent, to $117.59.

  • Early Glance: Biotechnology companies Monday, 13 Apr 2015 | 10:27 AM ET

    Amgen Inc. rose$. 71 or. 4 percent, to $164.09. Biogen Idec rose $4.25 or 1.0 percent, to $429.89. Celgene Corp. rose$. 35 or. 3 percent, to $117.42.

  • Earnings outlook grows bleak. What to buy Wednesday, 1 Apr 2015 | 12:16 PM ET
    A file photo of a FedEx truck

    The upcoming earnings season is forging a bleak outlook for investors. CNBC Pro highlights some of the top picks on the street.

  • Cramer: The best places for you to put new money Monday, 30 Mar 2015 | 6:55 PM ET
    A Cofor worker wearing a safety hard hat moves drilling pipes near to a rig at the geothermal energy drilling site operated by Semhach SA in Villejuif, France.

    Jim Cramer reveals the top places to invest new money on the stock market.

  • March 26- French drugmaker Genfit SA said on Thursday it will begin a late stage trial later this year of its lead treatment for a liver-destroying condition, saying it failed a midstage trial in part due to its inclusion of many patients with a mild form of the disease. When adjusting for those factors, the results were "quite robust for NASH," Dean Hum, the company's...

  • Biotech woes: Deja vu all over again Thursday, 26 Mar 2015 | 12:59 PM ET
    Biotech

    For biotech watchers, it's deja vu all over again. Through Wednesday, the Nasdaq Biotechnology Index dropped 6.9 percent since the close March 20.

  • March 26- Conatus Pharmaceuticals Inc said its experimental lead drug was more effective than a placebo in a mid-stage study in patients with a form of fatty liver disease. Several drugmakers, including Gilead Sciences Inc, Intercept Pharmaceuticals Inc and France's Genfit SA, are in the race to develop treatments. Conatus estimates that about 2 million...